Novel approaches in the treatment of Hansen’s disease (Leprosy): a case series of multidrug therapy of monthly rifampin, moxifloxacin, and minocycline (RMM) in the United States

Carlos Franco-Paredes, Elizabeth Garcia-Creighton, Andrés Henao-Martínez, Diane L. Kallgren, Rashmi Banjade, Jon A. Dyer, Taylor Nelson, Araya Zaesim, Michael J. Peluso, Vivek Jain, Dong Heun Lee, Lucio R. Minces, Mary Wirshup, Miguel Sierra Hoffman, Jenn Katsolis, Karen Brust, Jose Giron, Lauren Smiarowski, Pauline A. Hoosepian-Mer, Barbara Stryjewska

Research output: Contribution to journalArticlepeer-review

3 Scopus citations

Abstract

The World Health Organization (WHO) recommends multidrug therapy (MDT) for the treatment of paucibacillary and multibacillary forms of leprosy, also known as Hansen’s disease (HD). MDT combinations of dapsone, rifampin, and clofazimine have reduced the prevalence of the disease but are not without adverse effects impacting regimen adherence. Hence, an urgent need exists to consider alternative MDT regimens with an improved safety profile that promotes treatment adherence. Herein, we described a case series of 10 patients with HD (nine patients with multibacillary leprosy and one with pure neural leprosy) treated with monthly rifampin, moxifloxacin, and minocycline (RMM). The United States National Hansen’s Disease Program (NHDP) diagnosed and treated patients across US institutions. All patients received a regimen of 12–24 months of RMM. We reviewed the clinical outcomes, adherence, rate of completion, and adverse events of patients treated with monthly RMM from January 2019 to August 2022. Nine patients had multibacillary leprosy, with some having type-2 reactions. One patient had pure neural leprosy with a reversal reaction. In this case series, we identified that all patients completed the RMM regimen without treatment interruptions. None of the patients experienced any skin hyperpigmentation or any significant side effects. All patients tolerated the monthly RMM regimen with rapid improvement of skin lesions and without logistic hurdles. Based on previous clinical evidence and the results of this case series, the NHDP and other programs should consider the RMM regimen as first-line therapy.

Original languageEnglish (US)
JournalTherapeutic Advances in Infectious Disease
Volume9
DOIs
StatePublished - 2022

All Science Journal Classification (ASJC) codes

  • Infectious Diseases
  • Pharmacology (medical)

Fingerprint

Dive into the research topics of 'Novel approaches in the treatment of Hansen’s disease (Leprosy): a case series of multidrug therapy of monthly rifampin, moxifloxacin, and minocycline (RMM) in the United States'. Together they form a unique fingerprint.

Cite this